Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

NCT06272695 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: R477-203
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 2

Brief Summary

This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes. After informed consent, Screening procedures to establish subject eligibility will be performed within a period of 28 days. Approximately 24 subjects with type 1 diabetes mellitus (T1DM) on stable doses of insulin will be enrolled. After enrollment, subjects will undergo a baseline Hypoglycemia Recovery Procedure (with glucagon rescue). Subjects will then receive volagidemab subcutaneously (SC) once weekly for 6 weeks. At the end of the treatment phase, subjects will undergo a second Hypoglycemia Recovery Procedure. Subjects will be followed for 6 weeks after the last volagidemab dose with a final End-of-Study (EOS) visit during Week 12. The primary outcome will be the change in time to glucagon treatment success at Week 6 versus baseline.

Conditions

Type 1 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Change in Time to glucagon treatment success at Week 6.

  The primary outcome of the study is the change in time to glucagon treatment success, defined as an increase in plasma glucose of ≥20 mg/dL from the glucose nadir after receiving glucagon during insulin-induced hypoglycemia, from baseline to Week 6.

  6 weeks

Secondary Outcomes (6)

• Blood glucose response to glucagon rescue treatment during insulin-induced hypoglycemia.

  6 weeks

• Treatment emergent adverse events (AEs)

  12 weeks

• Hypoglycemia symptoms - Edinburgh Hypoglycemia Scale

  6 weeks

• Hypoglycemia symptoms - Clarke Survey

  6 weeks

• Hypoglycemia symptoms - Gold Questionnaire

  6 weeks

Study Arms (1)

35 mg Volagidemab

EXPERIMENTAL

Volagidemab 35 mg will be administered by subcutaneous (SC) injection once weekly for 6 weeks.

Biological: Volagidemab

Interventions

Volagidemab BIOLOGICAL

Administered by SC injection once weekly for 6 weeks

35 mg Volagidemab

Eligibility Criteria

• Age: 18 Years - 72 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Receiving insulin for the treatment of documented diagnosis of T1DM for at least 2 years
• Body Mass Index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
• On treatment with a stable insulin regimen for at least 8 weeks
• Currently using a continuous glucose monitoring (CGM) system
• HbA1c less than or equal to 10.0%
• Females of non-childbearing potential must be ≥1 year post-menopausal or documented as being surgically sterile. Females of childbearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product
• Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 3 months after the end of the treatment period

You may not qualify if:

• History of type 2 diabetes, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
• Pancreas, pancreatic islet cells, or renal transplant recipient
• T1DM treatment with any other antihyperglycemic drug (e.g., metformin, alpha- glucosidase inhibitors, SGLT-2 inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 30 days of Day 1
• Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months prior to Day 1
• Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident ≤12 weeks
• Indication of liver disease
• Current signs and symptoms of anemia
• Untreated eating disorders such as bulimia or anorexia nervosa
• History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN.
• Treatment with systemic corticosteroids within 30 days of Day 1, or planned initiation of such therapy during the study.
• Medical history of cancer or treatment for cancer in the last five years
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial

Sponsors & Collaborators

• REMD Biotherapeutics, Inc.: lead

Study Sites (2)

Altman Clinical and Translational Research Institute

San Deigo, California, 92037, United States

Location

Diablo Clinical Research

Walnut Creek, California, 94598, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

volagidemab

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Zung Thai, MD

  REMD Biotherapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 15, 2024
• First Posted: February 22, 2024
• Study Start: February 15, 2024
• Primary Completion: February 1, 2025
• Study Completion: February 1, 2025
• Last Updated: June 3, 2025

Record last verified: 2025-05

Locations

US (2)